The dopamine D2 receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with l-dopa (original) (raw)
References
Ahlskog JE, Muenter MD (2001) Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16:448–458 ArticleCASPubMed Google Scholar
Akai T, Yamaguchi M, Mizuta E, Kuno S (1993) Effects of terguride, a partial D2 agonist, on MPTP-lesioned parkinsonian cynomolgus monkeys. Ann Neurol 33:507–511 ArticleCASPubMed Google Scholar
Akai T, Ozawa M, Yamaguchi M, Mizuta E, Kuno S (1995) Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J Pharmacol Exp Ther 273:309–314 CASPubMed Google Scholar
Andree TH, Stack G, Rosenzweig-Lipson S, Coupet J (1999) WAY-135452: a potent novel D2/D3 partial agonist for the treatment of schizophrenia. In: 38th annual meeting of the American College of Neuropsychopharmacology
Baronti F, Mouradian MM, Conant KE, Giuffra M, Brughitta G, Chase TN (1992) Partial dopamine agonist therapy of levodopa-induced dyskinesias. Neurology 42:1241–1243 CASPubMed Google Scholar
Bravi D, Davis TL, Mouradian MM, Chase TN (1993) Treatment of Parkinson’s disease with the partial dopamine agonist EMD 49980. Mov Disord 8:195–197 ArticleCASPubMed Google Scholar
Brucke T, Bankiewicz K, Harvey-White J, Kopin I (1988) The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model. Eur J Pharmacol 148:445–448 ArticleCASPubMed Google Scholar
Carlsson A (1983) Dopamine receptor agonists: intrinsic activity vs. state of receptor. J Neural Transm 57:309–315 ArticleCASPubMed Google Scholar
De Vries MH, Hesselink MB, Winsemius AA, Jenner P, Johnston L, Salvage S (2004) SLV 308: plasma levels of effective doses in MPTP-treated marmosets in comparison with plasma levels and D2 receptor occupancy (PET) in humans. Clin Pharmacol Ther 75:70 Article Google Scholar
Glennon JC, Van SG, Ronken E, Hesselink MB, Reinders JH, Van Der NM, Long SK, Feenstra RW, McCreary AC (2006) In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2(3H)-benzoxazolone, monohydrochloride): a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse 60:599–608 ArticleCASPubMed Google Scholar
Heinrich JN, Brennan J, Lai MH, Sullivan K, Hornby G€piolek M, Jiang LX, Pausch MH, Stack G, Marquis KL, Andree TH (2006) Aplindore (DAB-452), a high affinity selective dopamine D2 receptor partial agonist. Eur J Pharmacol 552:36–45 ArticleCASPubMed Google Scholar
Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, exander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O’Connell C, Ross T, Richard K, Watts A (2004) Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61:1044–1053 ArticlePubMed Google Scholar
Jackson MJ, Smith LA, Al-Barghouthy G, Rose S, Jenner P (2007) Decreased expression of l-dopa-induced dyskinesia by switching to ropinirole in MPTP-treated common marmosets. Exp Neurol 204:162–170 ArticleCASPubMed Google Scholar
Jenner P (2008a) Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 9:665–677 ArticleCASPubMed Google Scholar
Jenner P (2008b) Preventing and controlling dyskinesia in Parkinson’s disease—a view of current knowledge and future opportunities. Mov Disord 23(Suppl 3):S585–S598 Google Scholar
Kehne JH, Andree TH, Heinrich JN (2008) D2 receptor partial agonists: treatment of CNS disorders of dopamine function. Curr Top Med Chem 8:1068–1088 ArticleCASPubMed Google Scholar
Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349–379 ArticleCASPubMed Google Scholar
Kuoppamaki M, Al-Barghouthy G, Jackson MJ, Smith LA, Quinn N, Jenner P (2007) L-dopa dose and the duration and severity of dyskinesia in primed MPTP-treated primates. J Neural Transm 114:1147–1153 ArticleCASPubMed Google Scholar
Lange KW, Loschmann PA, Wachtel H, Horowski R, Jahnig P, Jenner P, Marsden CD (1992) Terguride stimulates locomotor activity at 2 months but not 10 months after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine treatment of common marmosets. Eur J Pharmacol 212:247–252 ArticleCASPubMed Google Scholar
Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M (1987) Advanced Parkinson’s disease: use of partial dopamine agonist, ciladopa. Neurology 37:863–865 CASPubMed Google Scholar
Martignoni E, Pacchetti C, Aufdembrinke B, Godi L, Albani G, Mancini F, Nappi G (1995) Terguride in stable Parkinson’s disease. Funct Neurol 10:143–146 CASPubMed Google Scholar
Obeso JA, Olanow CW, Nutt JG (2000) Levodopa motor complications in Parkinson’s disease. Trends Neurosci 23:S2–S7 ArticleCASPubMed Google Scholar
Pacchetti C, Martignoni E, Bruggi P, Godi L, Aufdembrinke B, Miltenburger C, Voet B, Nappi G (1993) Terguride in fluctuating parkinsonian patients: a double-blind study versus placebo. Mov Disord 8:463–465 ArticleCASPubMed Google Scholar
Pearce RK, Jackson M, Smith L, Jenner P, Marsden CD (1995) Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1, 2, 3, 6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus). Mov Disord 10:731–740 ArticleCASPubMed Google Scholar
Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342:1484–1491 ArticleCASPubMed Google Scholar
Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL (2003) Limitations of current Parkinson’s disease therapy. Ann Neurol 53(Suppl 3):S3–S12 Google Scholar
Ruggieri S, Stocchi F, Baronti F, Viselli F, Horowski R, Lucarelli C, Agnoli A (1991) Antagonist effect of terguride in Parkinson’s disease. Clin Neuropharmacol 14:450–456 ArticleCASPubMed Google Scholar
Smith LA, Jackson MJ, Hansard MJ, Maratos E, Jenner P (2003) Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 18:487–495 ArticlePubMed Google Scholar
Stephenson RP (1956) A modification of receptor theory. Br J Pharmacol Chemother 11:379–393 CASPubMed Google Scholar